The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| A | +6.65% | +33.26% | +5.91% | +483% |
| S&P | +12.66% | +85.37% | +13.13% | +381% |
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
These exchange-traded funds track companies in this biotech space.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.86B | 9.4% |
| Gross Profit | $1.01B | 9.5% |
| Gross Margin | 54.43% | 0.1% |
| Market Cap | $41.49B | 10.8% |
| Market Cap / Employee | $2.31M | 8.4% |
| Employees | 18K | 3.4% |
| Net Income | $434.00M | 23.6% |
| EBITDA | $514.00M | 3.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.79B | 34.6% |
| Accounts Receivable | $1.49B | 12.3% |
| Inventory | 1K | 5.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.05B | -12.5% |
| Short Term Debt | $304.00M | 249.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 10.57% | -0.8% |
| Return On Invested Capital | 13.59% | -0.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $452.00M | 16.5% |
| Operating Free Cash Flow | $545.00M | 13.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 34.82 | 26.54 | 26.92 | 32.02 | 8.77% |
| Price to Book | 7.33 | 5.09 | 5.31 | 6.52 | 2.66% |
| Price to Sales | 6.66 | 4.63 | 4.82 | 5.98 | 4.14% |
| Price to Tangible Book Value | 49.44 | 28.31 | 27.93 | 29.11 | 20.10% |
| Price to Free Cash Flow TTM | 41.98 | 33.63 | 40.50 | 47.78 | 40.40% |
| Enterprise Value to EBITDA | 98.66 | 76.52 | 75.70 | 83.91 | 5.20% |
| Free Cash Flow Yield | 2.4% | 3.0% | 2.5% | 2.1% | -28.77% |
| Return on Equity | 20.6% | 18.9% | 19.9% | 20.6% | -6.08% |
| Total Debt | $3.36B | $3.50B | $3.41B | $3.35B | -6.16% |
No podcast episodes available.
A earnings call for the period ending June 30, 2022.
A earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
